Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Baillie Gifford - International Alpha. This analysis is provided for institutional research purposes only and is not investment advice.
"International equities broke their 13-year underperformance streak in Q1 2025, led by Europe's fiscal stimulus and China's regulatory improvements. The manager opportunistically bought Novo Nordisk after its 50% decline, capitalizing on the GLP-1 obesity opportunity."
International equities outperformed US markets in Q1 2025, breaking a 13-year streak of US dominance driven by the Magnificent Seven tech concentration. The manager sees this as a structural shift, with international markets offering lower valuations and less concentration risk than the US market where the top 10 S&P 500 companies reached 40% of the index. Europe led international performance, benefiting from faster interest rate cuts, increased lending, and significant fiscal stimulus including Germany's 500 billion euro infrastructure fund. The manager capitalized on market volatility by purchasing Novo Nordisk after its 50% decline, viewing it as an exceptional growth opportunity in GLP-1 obesity treatments. Chinese stocks also performed well due to fiscal stimulus and improved regulatory conditions for non-SOE companies. The portfolio's diversified approach across quality compounders, rapid growth companies, and capital allocators provides resilience for expected continued market turbulence. Quality defensive names like Unilever are positioned to outperform in any recessionary environment ahead.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High conviction expressed in the structural shift toward international outperformance and specific investment decisions like Novo Nordisk purchase. Clear articulation of investment thesis and portfolio positioning with strong supporting rationale.
Growth Outlook
The manager expresses cautious optimism about international markets breaking their long underperformance streak, with positive developments in Europe and China. However, this is tempered by expectations of continued market turbulence and choppy waters ahead.
Risk Appetite
The positioning is moderately constructive with selective deployment (buying Novo Nordisk) but emphasizes defensive characteristics and resilience. The focus on quality compounders and diversification suggests a balanced rather than aggressive risk appetite.
Capital Deployment
Modest capital deployment evidenced by the Novo Nordisk purchase after waiting for attractive valuation. The manager is selectively adding positions but emphasizes patience and valuation discipline rather than aggressive deployment.
Forward Guidance
Forward guidance is cautiously neutral, acknowledging probable continued market turbulence while expressing confidence in portfolio resilience. The manager is positioned defensively for difficult conditions rather than aggressively deploying capital.
Language Signal
Language contains more positive signals around international opportunities, European rejuvenation, and attractive valuations, balanced against references to turbulence and choppy waters. Net positive but measured tone.
Perceived Risk
Moderate to high risk perception with explicit acknowledgment that turbulence has become the new normal and expectation of more choppy waters ahead. However, confidence in portfolio resilience moderates the overall risk assessment.
Opportunity Density
Moderate opportunity density with specific attractive opportunities identified in international markets, particularly Europe and select growth companies like Novo Nordisk. Opportunities are selective rather than broad-based.
Time Horizon
Strong long-term orientation evidenced by 5-10 year outlook for Novo Nordisk, emphasis on compounding growth companies, and willingness to wait for attractive valuations. Patient capital approach clearly articulated.
